Cargando…

Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy

Acute kidney injury (AKI) complicates the clinical course of hospitalized patients by increasing need for intensive care treatment and mortality. There is only little data about its impact on AML patients undergoing intensive induction chemotherapy. In this study, we analyzed the incidence as well a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ballo, Olivier, Eladly, Fagr, Büttner, Stefan, Stratmann, Jan Alexander, Rudolf, Sarah, Brunnberg, Uta, Kreisel, Eva-Maria, Steffen, Björn, Wagner, Sebastian, Finkelmeier, Fabian, Serve, Hubert, Brandts, Christian H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043920/ https://www.ncbi.nlm.nih.gov/pubmed/33704529 http://dx.doi.org/10.1007/s00277-021-04482-3

Ejemplares similares

Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2021)

Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2020)

Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy
por: Ballo, Olivier, et al.
Publicado: (2019)

Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations
por: Koschade, Sebastian E., et al.
Publicado: (2022)

Diagnostic yield, indications, and outcomes of cranial imaging in AML patients admitted for intensive induction or consolidation chemotherapy: a single-center experience
por: Koschade, Sebastian E., et al.
Publicado: (2023)

Bone Marrow Assessment in Liver Cirrhosis Patients with Otherwise Unexplained Peripheral Blood Cytopenia
por: Koschade, Sebastian E., et al.
Publicado: (2023)

Metabolic Plasticity of Acute Myeloid Leukemia
por: Kreitz, Johanna, et al.
Publicado: (2019)

Obesity is associated with an impaired survival in lymphoma patients undergoing autologous stem cell transplantation
por: Scheich, Sebastian, et al.
Publicado: (2019)

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012)

Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia
por: Koschade, Sebastian E., et al.
Publicado: (2022)

Correction: Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia
por: Koschade, Sebastian E., et al.
Publicado: (2022)

P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT
por: Cremer, Anjali, et al.
Publicado: (2023)

Treatment with midostaurin and other FLT3 targeting inhibitors is associated with an increased risk of cardiovascular adverse events in patients who underwent allogeneic hematopoietic stem cell transplantation with FLT3-mutated AML
por: Cremer, Anjali, et al.
Publicado: (2023)

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Weber, Sarah, et al.
Publicado: (2021)

Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

VCP inhibition induces an unfolded protein response and apoptosis in human acute myeloid leukemia cells
por: Szczęśniak, Paweł P., et al.
Publicado: (2022)

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment
por: Demirel, Özlem, et al.
Publicado: (2017)

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Berdel, Andrew F., et al.
Publicado: (2022)

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies
por: Kirschner, Martin, et al.
Publicado: (2022)

Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience
por: Enßle, Julius C., et al.
Publicado: (2023)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

Short Versus Long Antibiotic Therapy and Risk of Recurrence of Acute Cholangitis Due to Malignant Biliary Strictures
por: Ferstl, Philip G., et al.
Publicado: (2023)

Sweet’s Syndrome (SS) in the Course of Acute Myeloid Leukaemia (AML)
por: Guarneri, Claudio, et al.
Publicado: (2018)

Papular eruption after induction chemotherapy for acute myeloid leukemia
por: Novice, Taylor, et al.
Publicado: (2020)

Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?
por: Jaramillo, Sonia, et al.
Publicado: (2021)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry
por: Yoo, Kwai Han, et al.
Publicado: (2021)

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia
por: Eckardt, Jan-Niklas, et al.
Publicado: (2021)

P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13
por: Pfeifer, Heike, et al.
Publicado: (2023)

Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy – retrospective analysis of changes over 3 yr in a German hospital
por: Böhme, Angelika, et al.
Publicado: (2012)

Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia
por: Jeha, George M., et al.
Publicado: (2020)

Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management
por: Chen, Stella X., et al.
Publicado: (2021)

Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma
por: Himmelsbach, Vera, et al.
Publicado: (2021)

Fatal Idiopathic Hyperammonemia after Induction Chemotherapy for Acute Myeloid Leukemia
por: Angelo, Christophe, et al.
Publicado: (2020)

Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?
por: McCurdy, Shannon R., et al.
Publicado: (2021)

Neutropenic Enterocolitis Complicating Induction Chemotherapy in an Acute Myeloid Leukemia Patient
por: Groudan, Kevin, et al.
Publicado: (2021)

PB1854: EARLY SEVERE ADVERSE EVENTS OF ACUTE MYELOID LEUKEMIA THERAPY DEPENDING ON THE INDUCTION THERAPY REGIMEN
por: Mikhailov, Evgeniy, et al.
Publicado: (2023)

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
por: Lengfelder, Eva, et al.
Publicado: (2012)

Drug Repurposing for the Treatment of Acute Myeloid Leukemia
por: Andresen, Vibeke, et al.
Publicado: (2017)

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib
por: Schaab, C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7i3jkpgngrslj3kf7r7hrui5ue